Parameter trajectory analysis to identify treatment effects of pharmacological interventions.
The field of medical systems biology aims to advance understanding of molecular mechanisms that drive disease progression and to translate this knowledge into therapies to effectively treat diseases. A challenging task is the investigation of long-term effects of a (pharmacological) treatment, to establish its applicability and to identify potential side effects. We present a new modeling approach, called Analysis of Dynamic Adaptations in Parameter Trajectories (ADAPT), to analyze the long-term effects of a pharmacological intervention. A concept of time-dependent evolution of model parameters is introduced to study the dynamics of molecular adaptations. The progression of these adaptations is predicted by identifying necessary dynamic changes in the model parameters to describe the transition between experimental data obtained during different stages of the treatment. The trajectories provide insight in the affected underlying biological systems and identify the molecular events that should be studied in more detail to unravel the mechanistic basis of treatment outcome. Modulating effects caused by interactions with the proteome and transcriptome levels, which are often less well understood, can be captured by the time-dependent descriptions of the parameters. ADAPT was employed to identify metabolic adaptations induced upon pharmacological activation of the liver X receptor (LXR), a potential drug target to treat or prevent atherosclerosis. The trajectories were investigated to study the cascade of adaptations. This provided a counter-intuitive insight concerning the function of scavenger receptor class B1 (SR-B1), a receptor that facilitates the hepatic uptake of cholesterol. Although activation of LXR promotes cholesterol efflux and -excretion, our computational analysis showed that the hepatic capacity to clear cholesterol was reduced upon prolonged treatment. This prediction was confirmed experimentally by immunoblotting measurements of SR-B1 in hepatic membranes. Next to the identification of potential unwanted side effects, we demonstrate how ADAPT can be used to design new target interventions to prevent these.
Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. c.a.tiemann@tue.nl
Christian A
CA
Tiemann
Joep
J
Vanlier
Maaike H
MH
Oosterveer
Albert K
AK
Groen
Peter A J
PA
Hilbers
Natal A W
NA
van Riel
D000818:Animals; D008076:Cholesterol, HDL / Q000032:analysis / Q000378:metabolism; D019295:Computational Biology / Q000379:methods*; D004358:Drug Therapy; D006845:Hydrocarbons, Fluorinated / Q000493:pharmacokinetics / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000032:analysis / Q000378:metabolism; D008099:Liver / Q000737:chemistry / Q000378:metabolism; D000071518:Liver X Receptors; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009010:Monte Carlo Method; D057093:Orphan Nuclear Receptors / Q000819:agonists; D000069437:Pharmacological Phenomena; D010641:Phenotype; D015203:Reproducibility of Results; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000494:pharmacology; D014280:Triglycerides / Q000032:analysis / Q000378:metabolism; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
D008076:Cholesterol, HDL; D006845:Hydrocarbons, Fluorinated; D008079:Lipoproteins, VLDL; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D013449:Sulfonamides; D014280:Triglycerides; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides